Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL11232709 | 0.95 | LMNA (0.55) | LMNATHRBALDH1A1 | |
| Ethylene SCHEMBL5155337 | 0.95 | LMNA (0.55) | LMNATHRB | |
| SCHEMBL7927646 | 0.91 | LMNA (0.50) | LMNA | |
| Ethylene Glycol SCHEMBL5988402 | 0.88 | LMNA (0.46) | LMNA | |
| Propionaldehyde SCHEMBL1523503 | 0.84 | LMNA (0.67) | LMNATHRBALDH1A1MAPK1TDP1 | |
| SCHEMBL7344731 | 0.84 | LMNA (0.52) | LMNATHRBALDH1A1 | |
| Malonaldehyde SCHEMBL6704192 | 0.82 | LMNA (0.63) | LMNATHRBALDH1A1MAPK1TDP1 | |
| SCHEMBL11485155 | 0.82 | LMNA (0.63) | LMNATHRBALDH1A1MAPK1TDP1 | |
| SCHEMBL4293299 | 0.81 | LMNA (0.71) | LMNATHRBALDH1A1MAPK1TDP1 | |
| Acetaldehyde SCHEMBL212729 | 0.81 | LMNA (0.71) | LMNATHRBALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213398-A | Preparation method of polysubstituted furan derivative, bactericide and application | 湖北省生物农药工程研究中心 | 2022-03-22 | — | — | CN | claimed |
| CN-108326470-B | Environment-friendly water cleaning type soldering flux | 五河县俊宝钢结构有限公司 | 2020-12-04 | — | — | CN | claimed |
| CN-104370851-A | Synthesis method of 2-aminomethyl-thiazole hydrochloride | KEJIE BIO SUZHOU PHARMACEUTICALS CO LTD | 2015-02-25 | — | — | CN | claimed |
| US-8524846-B1 | Trianionic ligand precursor compounds and uses thereof in constrained geometry catalysts | THE UNIVERSITY OF TOLEDO (US) | 2013-09-03 | — | — | US | claimed |
| EP-0470127-B1 | PCP RECEPTOR LIGANDS AND THE USE THEREOF | OREGON STATE (US) | 2003-02-26 | — | — | EP | claimed |
| EP-0247234-B1 | PROCESS FOR THE MANUFACTURE OF ACETALS OF CHLORO- OR BROMOACETALDEHYDE | National Starch and Chemical Corporation (US) | 1990-01-17 | — | — | EP | claimed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| WO-2025026555-A1 | ALDOXIMES AS NO DONORS, AND THEIR USES AS PLANT ARCHITECTURE MODIFIERS AND IN THERAPY | Universidad Pública de Navarra (ES) | 2025-02-06 | — | — | WO | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-4017844-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
| US-4085125-A | 9-Thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4066675-A | PSORIASIS, THROMBOSIS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4062868-A | Synthesis of biotin | HOFFMANN-LA ROCHE INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4044131-A | B-ADRENERGIC BLOCKERS, FUNGICIDES, 4-ALKYL OR ALKYNYL, 6-ARYLOXYMETHYL | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-08-23 | — | — | US | disclosed |
| US-4031228-A | 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anti-protozoal activity | SYNTEX (U.S.A.) INC. (US) | 1977-06-21 | — | — | US | disclosed |
| US-4018802-A | SKIN DISEASES, GROWTH HORMONE STIMULANTS, THROMBUS PREVENTION, IMMUNOLOGY | MERCK & CO., INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-3962437-A | 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity | SYNTEX (U.S.A.) INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | LMNA 2655/4885THRB 2587/4885ALDH1A1 1457/4885 |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | LMNA 2873/4885THRB 4190/4885ALDH1A1 1561/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | LMNA 4322/4885THRB 3303/4885ALDH1A1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.